Savara Inc. Announces Executive Changes
Ticker: SVRA · Form: 8-K · Filed: Jan 23, 2025 · CIK: 1160308
| Field | Detail |
|---|---|
| Company | Savara Inc (SVRA) |
| Form Type | 8-K |
| Filed Date | Jan 23, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, management
TL;DR
Savara's CMO is out, a new interim CMO is in. Executive shake-up.
AI Summary
Savara Inc. announced on January 23, 2025, the departure of Dr. Robert L. Neville as Chief Medical Officer and the appointment of Dr. Claire Davies as interim Chief Medical Officer. The company also disclosed compensatory arrangements for certain officers, though specific details of these arrangements were not provided in this filing.
Why It Matters
Changes in key executive positions can signal shifts in company strategy or operational focus, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: medium — Executive departures and appointments, especially interim ones, can introduce uncertainty regarding leadership stability and strategic direction.
Key Players & Entities
- Savara Inc. (company) — Registrant
- Dr. Robert L. Neville (person) — Departing Chief Medical Officer
- Dr. Claire Davies (person) — Interim Chief Medical Officer
- January 23, 2025 (date) — Date of Report
FAQ
Who has been appointed as the interim Chief Medical Officer at Savara Inc.?
Dr. Claire Davies has been appointed as the interim Chief Medical Officer.
When was the report filed with the SEC?
The report was filed on January 23, 2025.
What was Dr. Robert L. Neville's role at Savara Inc. before his departure?
Dr. Robert L. Neville was the Chief Medical Officer.
What other items are mentioned in the filing besides executive changes?
The filing also mentions compensatory arrangements of certain officers.
What is Savara Inc.'s state of incorporation?
Savara Inc. is incorporated in Delaware.
Filing Stats: 613 words · 2 min read · ~2 pages · Grade level 12.6 · Accepted 2025-01-23 16:05:39
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share SVRA The Nasdaq Global Se
Filing Documents
- d898630d8k.htm (8-K) — 29KB
- 0001193125-25-011453.txt ( ) — 149KB
- svra-20250123.xsd (EX-101.SCH) — 3KB
- svra-20250123_lab.xml (EX-101.LAB) — 18KB
- svra-20250123_pre.xml (EX-101.PRE) — 11KB
- d898630d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 23, 2025 SAVARA INC. a Delaware corporation By: /s/ Dave Lowrance Dave Lowrance Chief Financial & Administrative Officer